Daxxify vs Botox: What the FDA Labels Actually Say About Duration, Formula, and Dose

Read this first: Express Med Spa does not offer Daxxify. Our four Chicagoland clinics carry Botox® Cosmetic, Xeomin®, and Letybo®. We have never injected Daxxify® and we have no patient experience with it, so everything this article says about it comes from the FDA-approved prescribing information or from what its manufacturer has published, and it is labeled that way every time. If Daxxify is what you want, you will need a provider who stocks it. Nothing below is an attempt to talk you out of it.

Daxxify arrived with one claim attached: that it lasts longer. That claim is why this comparison gets searched so heavily, and it is also the part most often reported carelessly.

So rather than summarize what clinics say about Daxxify, this article goes to the documents that govern what can be said: the FDA-approved prescribing information for each product. Where the manufacturer makes a claim the label does not carry, we say so and attribute it. That produces a few findings that contradict what you will read almost everywhere else.

Here is the short version.

• Daxxify is stabilized with a peptide instead of albumin. It is the only one of the four products discussed here whose label does not list human albumin as an ingredient.
• The duration claim is the manufacturer’s, not the label’s. The Daxxify prescribing information states no duration-of-effect figure for frown lines at all. The six-month median comes from Revance Therapeutics’ own approval announcement.
• Its cosmetic approval is narrower. Daxxify is approved for frown lines between the brows. Botox Cosmetic’s label covers four facial areas.
• The dose numbers are not comparable. The approved frown-line dose is 40 units of Daxxify and 20 units of Botox Cosmetic. Both labels state their units cannot be converted into any other product’s units.
• Neither product is safer or better than the other. Same class boxed warning, different unit scales. We make no comparative claim in either direction.

What is Daxxify?

Daxxify is the brand name for daxibotulinumtoxinA-lanm, a botulinum toxin type A injectable. Its FDA-approved prescribing information lists Revance Therapeutics, Inc. as its manufacturer and records an initial United States approval date of 2022. The label gives it two approved indications, both in adults:

• Temporary improvement in the appearance of moderate to severe glabellar lines, the clinical term for the vertical frown lines between the brows that people call the elevens.
• Treatment of cervical dystonia, a medical condition involving involuntary neck muscle contraction. That is a therapeutic use, not a cosmetic one.

Mechanically it does what every product in this class does. The label describes it as blocking neuromuscular transmission by inhibiting the release of acetylcholine, with the neurotoxin cleaving a protein called SNAP-25 that the nerve ending needs to release that signal. No signal, less contraction, softer expression line. Recovery is gradual, which is why the effect is temporary in every product of this type.

None of that separates it from Botox Cosmetic. The separation is in the vial.

The peptide: what replacing albumin actually changes, and what it does not

This is the genuine formulation difference, and it is worth getting right because it is routinely conflated with a different one.

The Daxxify label’s Description section states that daxibotulinumtoxinA-lanm is a 150 kDa botulinum toxin without accessory proteins, formulated with a 35 amino acid peptide excipient designated RTP004, which the label says “prevents surface adsorption and promotes thermal stability.” Each vial contains 50 or 100 units of toxin along with L-histidine, L-histidine hydrochloride monohydrate, polysorbate 20, 11.7 micrograms of the RTP004 peptide, and trehalose dihydrate. Human albumin is not on that list.

The Botox Cosmetic label, by contrast, describes a purified botulinum toxin type A refined “to a complex consisting of the neurotoxin, and several accessory proteins,” then dissolved in a sterile sodium chloride solution “containing Albumin Human.” Each 50 unit vial contains 0.25 mg of Albumin Human.

So far this reads like the familiar story: one product has extra proteins and a blood-derived stabilizer, the other has neither. Here is where the familiar story breaks down.

“No accessory proteins” and “no albumin” are two different claims

Xeomin is the product most often described as the purified or naked one, and that description is accurate as far as it goes: its prescribing information yields a 150 kDa neurotoxin “without accessory proteins,” the same phrasing the Daxxify label uses. But the Xeomin label also states that each vial contains human albumin, at 1 mg. In other words, being free of accessory proteins does not make a product free of albumin. Daxxify is distinctive not because it is purified, but because of what it uses in place of a blood-derived stabilizer.

Side by side, according to the two labels:

Formulation as stated in each product’s FDA-approved prescribing informationFormulationBotox CosmeticDaxxifyEstablished nameonabotulinumtoxinAdaxibotulinumtoxinA-lanmAccessory proteinsYes, supplied as a toxin complexNo, 150 kDa without accessory proteinsStabilizer listed on the labelAlbumin Human, 0.25 mg per 50 unit vial35 amino acid peptide (RTP004), 11.7 mcg per vial

Is albumin something to worry about?

We are not going to let this section imply something the labels do not support, so here is the labeling itself. Products containing human albumin carry a section headed “Human Albumin and Transmission of Viral Diseases.” On the Botox Cosmetic label it reads: “This product contains albumin, a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries a remote risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease (vCJD). There is a theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD), which would also be considered remote. No cases of transmission of viral diseases, CJD or vCJD have ever been identified for licensed albumin or albumin contained in other licensed products.”

Note what that says and does not say. It discloses a risk, characterizes it twice as remote, describes one part of it as theoretical, and states that no case has ever been identified. That is a disclosure, not a warning to avoid the product. Botox Cosmetic has been approved in the United States since 1989 on that basis.

So the honest read is this: the peptide formulation is a real difference, but it is not, on the published evidence, a safety upgrade worth switching products to obtain. If avoiding a blood-derived excipient matters to you personally, that is a legitimate preference to raise with a provider who carries the product.

Does Daxxify last longer than Botox?

This is the question the whole comparison exists for, and the answer has two parts that most articles run together.

Part one: what the FDA label says

The Daxxify prescribing information contains no duration-of-effect figure for frown lines. There is no statement that results last six months, or four months, or any number of months. We read the Clinical Studies section specifically looking for one.

What the label does describe is the trial design. Two randomized, double-blind, placebo-controlled studies enrolled 609 adults with at least moderate frown lines. A total of 406 subjects were treated with 40 units of Daxxify and 203 received placebo. The primary endpoint was measured at week 4, and 74 percent of treated subjects in each study met it, against 0 percent on placebo. Subjects were followed for at least 24 weeks, and the label presents a figure tracking the proportion still rated none or mild out to 36 weeks, with subjects discontinued once their scores returned to baseline.

Followed for 24 weeks is not the same thing as an approved claim that results last 24 weeks. The label reports how long people were watched; it does not convert that into a duration claim. It does carry one timing instruction that is easy to miss: Daxxify “should be administered no more frequently than every three months for any indication.”

Part two: what the manufacturer says

The widely repeated six-month figure is real, and it has a specific source. In its announcement of the FDA approval, Revance Therapeutics described Daxxify as having a “median duration of six months and up to nine months for some patients,” based on its clinical program, which the company said included more than 2,700 patients and approximately 4,200 treatments.

That is a manufacturer statement about its own trial program, and we are not suggesting it is fabricated. But it belongs in a different evidentiary category than an FDA-approved labeling claim, and a reader choosing between products deserves to know which category it sits in. The word “median” matters here too: a median is the middle of a distribution, which means by definition that a large share of patients came in under it, and “up to nine months for some patients” describes the upper tail rather than a typical outcome.

What Botox Cosmetic patients typically see

For comparison, our own patients most commonly see Botox Cosmetic results lasting three to four months, with duration influenced by treatment history, the area treated, muscle strength, and the dose used. Our Botox Cosmetic treatment page covers that in detail.

We are deliberately not turning that into a head-to-head statement. The two duration figures come from separate trial programs using different endpoints, severity scales, and assessment schedules, and lining them up as though they were measured the same way is the mistake this section exists to help you avoid. Individual results vary and no injectable outcome can be guaranteed.

The practical question to ask any provider offering Daxxify is not “does it last six months.” It is “what have your patients actually gotten, and what happens if my result fades at three.”

Why the dose numbers look so different

If you compare the approved frown-line regimens, the numbers appear to be twice as far apart as they are:

• Daxxify: 40 units total, delivered as 8 units into each of five sites, two injections into each corrugator muscle and one into the procerus.
• Botox Cosmetic: 20 units total, delivered as 4 units into each of five sites.

Same muscles, same five injection points, a unit count that differs by a factor of two. That does not mean Daxxify is twice as much product. It means the two count in different currencies, and both labels say so. The Daxxify label states that its potency units “are specific to the preparation and test method utilized. They are not interchangeable with other preparations of botulinum toxin products.” The Botox Cosmetic label states that units of its biological activity “cannot be compared to nor converted into Units of any other botulinum toxin or any toxin assessed with any other specific assay method.”

The consequence for a patient is short and worth remembering: a unit count means nothing until you know which product it belongs to, and a per-unit price means nothing either.

We have written the unit-and-pricing mechanics up in full, including the arithmetic that turns a lower per-unit price into an identical total, in our Dysport vs Botox guide. That is the right place for the deep version, so this one does not repeat it.

What each product is actually approved to treat

This is a straightforward label comparison, and one of the more useful differences because it is often left out entirely.

Botox Cosmetic is indicated in adults for moderate to severe glabellar lines, lateral canthal lines (crow’s feet), forehead lines, and platysma bands, the vertical cords in the neck. Four areas. Daxxify is indicated in adults for moderate to severe glabellar lines: on the cosmetic side, one area.

A narrower label is not a verdict on a product’s capability, and it is common for these products to be approved in one area first and studied in others afterward. What a licensed clinician may decide to do in practice is a separate question from what a label covers, and one for the clinician treating you. But if you are choosing a product specifically for crow’s feet or forehead lines, the scope of the approved labeling is a reasonable thing to ask about.

How quickly does Daxxify start working?

Here the label is quiet again. The Daxxify prescribing information reports its primary efficacy endpoint at week 4 and states no onset figure. Revance’s approval announcement describes results “seen as early as one day after treatment, typically seen within two days,” which is the manufacturer’s characterization of its own program and is reported here as such rather than adopted.

Across this whole class, the number worth planning around is not the first day you notice something. It is the two-week mark, when a result has settled enough for an injector to assess it fairly and adjust if needed. Book anything you are treating for well ahead of that, whatever product is used.

Risks and side effects listed on the Daxxify label

Every botulinum toxin product carries the same class boxed warning. The Daxxify label warns that the effects of all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects, that these have been reported hours to weeks after injection, and that “swallowing and breathing difficulties can be life-threatening, and there have been reports of death.” Anyone who develops difficulty swallowing, speaking, or breathing after any neurotoxin treatment should seek immediate medical care.

For cosmetic use specifically, the label’s pooled placebo-controlled frown-line trials reported the following adverse reactions at 1 percent or more and more frequently than placebo:

• Headache, in 6 percent of treated subjects versus 2 percent on placebo.
• Eyelid ptosis, meaning a drooping upper lid, in 2 percent versus 0 percent on placebo.
• Facial paresis, including facial asymmetry, in 1 percent versus 0 percent on placebo.

Injection site reactions were reported in 6 percent of subjects on Daxxify and 6 percent on placebo. The label also describes an 84 week open-label repeat-dose study in which 2,691 subjects were treated with 40 units, with adverse reactions reported in 20 percent, and states that “the incidence of these adverse reactions did not increase with multiple re-treatments.” It lists two contraindications: known hypersensitivity to any botulinum toxin preparation, to Daxxify, or to any component of its formulation, and infection at the proposed injection sites.

We are not going to set those numbers against Botox Cosmetic’s and declare a winner. They come from separate trials with separate populations and separate reporting thresholds, and a table built from them would look rigorous while meaning very little. These are the same category of effects driven by the same mechanism, and in cosmetic use the factors that most influence whether they happen are dose, placement, and patient selection by a licensed clinician.

Botulinum toxin products are prescription medications and are not appropriate for everyone. Pregnancy, breastfeeding, certain neuromuscular conditions, active infection at the injection site, and some medications are all relevant.

What Express Med Spa offers instead of Daxxify

We carry three botulinum toxin type A products across all four clinics:

• Botox Cosmetic, the product most patients arrive asking for by name, and the one with the widest approved cosmetic labeling of the three.
• Xeomin, the 150 kDa formulation without accessory proteins.
• Letybo, a more recently approved option that some patients choose on their injector’s recommendation.

We do not carry Daxxify, and we are not going to use that as an excuse to run it down. It is an FDA-approved product with a real formulation innovation behind it. It is simply not on our shelf, and we would rather say so at the top of the page than have you book a consultation expecting it.

If the comparison you are actually weighing is a different pairing, each one has its own guide rather than a single roundup, because the answers genuinely differ: Xeomin vs Botox, Letybo vs Botox, and Dysport vs Botox.

Express Med Spa is nurse-practitioner-led, and injectable treatments are provided by licensed clinicians. Which product you receive, how many units, and where they go are decided at a consultation based on your anatomy, your treatment history, and what you want changed.

Where Express Med Spa offers Botox, Xeomin, and Letybo

Express Med Spa has four Chicagoland medical spa locations. Daxxify is not available at any of them.

• Frankfort, 11 S White St Suite 104, Frankfort, IL 60423. Phone 877-363-3772. Also serving New Lenox, Mokena, and Tinley Park.
• La Grange, 320 W Burlington Ave, La Grange, IL 60525. Phone 708-847-0872. See Botox in La Grange.
• Shorewood, 707 W Jefferson St Ste M, Shorewood, IL 60404. Phone 877-363-3772.
• Mount Greenwood (Chicago), 3314 W 111th St, Chicago, IL 60655. Phone 877-363-3772. See Botox and Xeomin in Mount Greenwood.

Daxxify vs Botox: frequently asked questions

Does Express Med Spa offer Daxxify?

No. Express Med Spa does not carry Daxxify at any of our four Chicagoland clinics. The botulinum toxin type A products we offer are Botox Cosmetic, Xeomin, and Letybo. If Daxxify is what you want, you will need to see a provider who stocks it.

Is Daxxify better than Botox?

Neither product is better. They are different formulations of the same class of drug, approved on separate clinical programs, dosed on separate unit scales, and carrying the same class boxed warning. Daxxify’s distinguishing feature is that it is stabilized with a peptide rather than human albumin. Botox Cosmetic’s approved cosmetic labeling covers more facial areas. Which one suits a given patient is a clinical decision, not a ranking.

Does Daxxify really last six months?

The six-month figure is a manufacturer statement, not an FDA-approved labeling claim. Revance Therapeutics described a median duration of six months, and up to nine months for some patients, when it announced the approval. The Daxxify prescribing information itself states no duration-of-effect figure for frown lines. A median also means roughly half of patients came in below it. Individual results vary and no outcome is guaranteed.

How is Daxxify different from Botox?

Two differences are documented in the labels. First, formulation: Daxxify is a 150 kDa toxin without accessory proteins, stabilized with a 35 amino acid peptide, and its label does not list human albumin. Botox Cosmetic is supplied as a toxin complex with accessory proteins and contains Albumin Human. Second, approved scope: Botox Cosmetic’s label covers four facial areas, while Daxxify’s cosmetic indication covers frown lines between the brows.

Is 40 units of Daxxify the same as 40 units of Botox?

No. Potency units are specific to each product and to the assay used to define them, and both labels state that their units cannot be converted into any other product’s units. The approved frown-line dose is 40 units of Daxxify and 20 units of Botox Cosmetic for the same five injection points. Never compare unit counts, or per-unit prices, across different products.

Is Daxxify safer than Botox because it has no human albumin?

The published labeling does not support that conclusion. Products containing human albumin carry a labeled disclosure describing a remote risk of viral transmission and a theoretical, also remote, risk relating to Creutzfeldt-Jakob disease, and stating that no case has ever been identified for licensed albumin. Avoiding a blood-derived excipient is a reasonable personal preference. It is not, on the evidence in the labels, a demonstrated safety advantage.

Is Daxxify approved for crow’s feet or forehead lines?

Not as of its current prescribing information. Daxxify’s cosmetic indication is moderate to severe glabellar lines. Botox Cosmetic’s label covers glabellar lines, lateral canthal lines, forehead lines, and platysma bands. What a clinician may do in practice is a separate question to raise with whoever is treating you.

Can I switch from Daxxify to Botox, or the other way around?

Patients move between botulinum toxin products regularly. Tell your injector which product you had and roughly how many units, because the dose has to be recalculated on the correct scale rather than carried across. Note also that the Daxxify label instructs that it be given no more frequently than every three months, so timing is worth confirming with your provider.

What are the side effects of Daxxify?

In the placebo-controlled frown-line trials described in its label, the reactions reported at 1 percent or more and more often than placebo were headache in 6 percent, eyelid ptosis in 2 percent, and facial paresis including facial asymmetry in 1 percent. Injection site reactions occurred in 6 percent on Daxxify and 6 percent on placebo. Like every product in the class it carries a boxed warning about toxin effects spreading from the injection site.

The honest bottom line

Daxxify is a real formulation innovation. Replacing a blood-derived stabilizer with a synthetic peptide is not a marketing flourish.

What has been oversold is the certainty around the duration claim. The six-month median is the manufacturer’s own figure from its own program, the FDA label carries no duration statement at all, and a median is a middle rather than a promise. If you go looking for Daxxify because you were told it lasts twice as long, go in knowing which of those is a labeling claim and which is not. The difference that gets the least attention is probably the most practical one: the two products’ approved cosmetic labeling does not cover the same areas of the face.

If you are in the Chicagoland area and want to talk through which neurotoxin fits you, Express Med Spa offers complimentary consultations with our nurse-practitioner-led team. We will tell you which products we carry and whether we think you are a good candidate at all. We will not tell you that the product we do not stock is a bad choice.

Book your consultation or contact us with a question first.

This article is general education, not medical advice, and it does not establish a clinician-patient relationship. Express Med Spa does not offer Daxxify and has no clinical experience with it; every statement about Daxxify above is drawn from its FDA-approved prescribing information or from published statements by its manufacturer, and is attributed accordingly. Botulinum toxin injectables are prescription products. Results vary from person to person and no outcome is guaranteed. Suitability is determined at a consultation with a licensed clinician. Refer to each product’s prescribing information for complete dosing, warnings, contraindications, and adverse event information.

BOTOX® and BOTOX® Cosmetic are registered trademarks of Allergan, Inc., an AbbVie company. DAXXIFY® is a registered trademark of Revance Therapeutics, Inc. Xeomin® is a registered trademark of Merz Pharma GmbH & Co. KGaA. Letybo® is a registered trademark of Hugel, Inc. Express Med Spa is not affiliated with, endorsed by, or sponsored by any of these companies. Product names are used for identification and comparison only.